GlassScriptPhysician profile
Allen R Smith
NPI 1255369138
$4,636.17
in general payments reported to CMS, 2019-2025
19 companies · $497 in 2025
The $497 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $101 · 2021: $302 · 2022: $286 · 2023: $495 · 2024: $2,643 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,084 · Food and Beverage: $1,535 · Entertainment: $16.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,084.40 |
| Food and Beverage | $1,534.52 |
| Entertainment | $16.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,671.63 | 2019-2025 | |
| Coopervision INC. | $497.69 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $284.67 | 2020-2025 | Precision7, Total30, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $213.99 | 2019-2021 | |
| Oyster Point Pharma, INC. | $159.72 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sight Sciences, INC. | $100.07 | 2023-2025 | Tearcare System |
| Bausch & Lomb Americas INC. | $90.08 | 2023-2025 | Xiidra, Infuse, Miebo |
| Optos, INC. | $85.01 | 2021-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $78.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $76.09 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $60.77 | 2025 | Xdemvy |
| Shire North American Group INC | $60.59 | 2019 | |
| Visioneering Technologies, INC. | $50.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $45.49 | 2021 | |
| Dompe US, INC. | $43.57 | 2022-2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.38 | 2021-2022 | |
| Lkc Technologies, INC. | $34.09 | 2024 | |
| Abbvie INC. | $25.57 | 2022 | |
| Spark Therapeutics, INC. | $18.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.